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Abstract 
BACKGROUND: Tuberculosis (TB) is one of the most common infectious diseases found in developing countries. 
One of the risk factors for TB is diabetes, a chronic metabolic disorder characterised by hyperglycemia. The 
altered in glucose metabolism will cause dysfunction of phagocyte and antibacterial that furthermore impaired 
activation of natural killer cells, dendritic cells. These together will alter the balance of T-cell immunity. Under 
hyperglycemic conditions, AGEs (advanced glycation end products) was increasingly formed and was believed to 
play a role in cell dysfunctions and diabetic complications. The CD4 deficiency will alter the immunity status in 
diabetes and TB with co-morbidity diabetes. 
AIM: This aim of this study was to evaluate CD4, and it’s relevant to Advanced Glycation End Products (AGEs) in 
TB with co-morbidity diabetes. 
METHODS: This is a case-control study with a total of 80 patients (40 diabetes and 40 TB with co-morbidity 
diabetes were recruited from Murni Teguh memorial Hospital Medan after ethical approval from Health Research 
Ethical Committee. The CD4, AGEs, Blood glucose and HbA1C were measured.  
RESULTS: There was no statistical difference of CD4, HbA1C and blood glucose within diabetes and TB with co-
morbidity diabetes but BMI (p = 0.009) and AGEs (p = 0.001) did. The CD4 below 500 were seen in 15% diabetes 
and 25% in TB with co-morbidity diabetes but did not show statistical significance difference (p = 0.07). No 
correlation was found between CD4 and AGEs in TB with co-morbidity diabetes (p = 0.44). 
CONCLUSION: The CD4 was not correlated significantly with AGEs. 
 
 
 
 
 
 
 
 
Introduction 
 
Tuberculosis (TB) is one of the most common 
infectious diseases found in developing countries, in 
Indonesia the prevalence remains very high despite 
the decrease [1].
 
Study about TB including the risk 
factors, multidrug-resistant play an important part in 
the prevention and treatment of the disease. One of 
the risk factors of TB is diabetes, a chronic metabolic 
disorder characterised by hyperglycemia resulting 
from a defect in insulin secretion or resistance [2]. 
Diabetes Mellitus (DM) is considered one of the 
largest non-infectious health problems in the world; it 
is estimated there will be 380 million of people with 
diabetes in 2025 with the most in developing countries 
[3]. The chronic state of low-grade inflammation due 
to increased formation of advanced glycation end 
products, activation of proinflammatory mediators, and 
the increase of oxidative stress will impair the 
phagocytic and antibacterial activity of neutrophils and 
macrophages, that can further impaired activation of 
natural killer cells, dendritic cells, that can impair T 
Cell-mediated immune responses, to promote the 
establishment of acute intracellular bacterial infections 
in diabetic patients. The increased incidence of 
intracellular bacterial infections is one of many 
diabetic's complications, one of the most common 
bacterial infection is TB [4] [5] [6] [7].
 
TBs is one of the most significant causes of 
death from intracellular bacterial infection especially in 
developing countries [8], data from a recent 
prospective study showed that diabetic patients have 
a threefold higher risk of developing TB, and at least 
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10-35% of patients with TB have co-morbidity 
diabetes [9]. 
The altered in host immune systems will 
increase the mortality of patients with TB and co-
morbidity diabetes and are more likely to have 
cavitary lung lesions, increased relapsed rate and 
most likely to develop multidrug resistance TB [10] 
[11]. Also, the treatment of TB with Rifampicin, one of 
the major TB drug will increase the metabolism of oral 
antidiabetic drugs thus may complicate the glycemic 
control [12] [13] [14]. 
 The altered in glucose metabolism will cause 
dysfunction of phagocyte and antibacterial that 
furthermore impaired activation of natural killer cells, 
dendritic cells. These together will alter the balance of 
T-cell immunity [15]. Under hyperglycemic conditions, 
AGEs (Advanced Glycation End Products) a group of 
heterogeneous compounds were increasingly formed 
and was believed to play a role in cell dysfunctions 
and diabetic complications [16]. Recent studies 
suggested that CD4 T cells are associated with 
control of chronic bacterial and viral infections [17] 
[18] [19], this also has been reported to play an 
important role in protective immunity against TB [20] 
[21]. The altered in the immune system and CD4 
deficiency will alter the immunity status that leads to 
death in diabetes and TBs with co-morbidity diabetes 
[22]. 
This study aimed to evaluate CD4 and its 
relevant with AGEs in TB patients with co-morbidity 
diabetes. 
 
 
Material and Methods 
 
This is a case-control study to evaluate CD4 
and its relevant with Advanced Glycation End 
Products (AGEs) in TBs patients with co-morbidity 
diabetes. The study received ethical approval from the 
Health Research Ethical Committee Medical Faculty 
Universitas Sumatera Utara/H.Adam Malik General 
Hospital Medan Indonesia (No.444/TGL/KEPK FK 
USU-RSUP HAM/2017). Only patients diagnosed with 
diabetes and who gave signed informed consent were 
admitted to the study. Patients were recruited 
between March 2017 and September 2017 from Murni 
Teguh Memorial Hospitals in Medan, Indonesia. A 
total of 80 patients (40 diabetes and 40 TB with co-
morbidity diabetes were recruited and was admitted 
into the study. Their age ranged between 36 years 
and 86 years (mean 60.0 ± 10.0 years) with the Body 
mass index ranged between 16.4 and 32.1 (mean 
23.8 ± 3.0). Their characteristics are shown in Table 
1.  
Blood sampling was performed from a clean 
venepuncture using the Vacutainer system (Beckton 
Dickenson, New Jersey, USA). About 6 mL of blood 
was collected into EDTA and heparin tubes. Both 
tubes spun for 15 min at 2000g within an hour of 
blood collection. Plasma EDTA and heparin samples 
were aliquoted and kept at -70°C until assayed.  
The following assays were performed: blood 
glucose, HbA1C, CD4, and AGEs was performed at 
the Integrated Laboratory Medical faculty University 
Sumatera Utara, Medan Indonesia. Blood glucose 
was measured with spectrophotometry, HbA1C with 
HPLC method, CD4 with flow cytometry, and AGEs 
with ELISA method. 
Body mass index was determined by using 
the BMI calculator with body weight and height.  
The Statistical Package for Social Sciences 
(SPSS22; SPSS Inc, Chicago, Il, USA) was used to 
perform the statistical analysis. Descriptive statistic 
and Non-parametric Mann Whitney U test were 
performed to evaluate the blood glucose, HbA1C, 
CD4, BMI and AGEs level in diabetes and TBs 
patients with co-morbidity diabetes. Spearman's Rho 
correlation analysis was used to determine the 
correlation between CD4 against AGEs seen in 
diabetes and TB patients with co-morbidity diabetes. 
A P value of less than 0.05 was considered 
statistically significant. 
 
 
Results 
 
In total, 80 patients were studied, (40 diabetes 
patients, 40 TB with co-morbidity diabetes). Their 
characteristics and Laboratory assays are shown in 
table 1. The parameter statistic was shown in table 2. 
The Box plots of CD4 and AGEs levels between 
diabetes and TB with co-morbidity diabetes are shown 
in Figure1 and 2. 
Table 1: Characteristic of the samples 
Group Mean Age 
(range) 
years 
Mean BMI 
(range) 
Mean Blood 
Glucose 
(range) 
mg/dl 
Mean 
HbA1C 
(range)% 
Mean CD4 
(range) 
Mean 
AGEs 
(range) 
μg/ml 
Diabetes  60 (44-73) 24.6 (19.9-
32.1) 
223 (85-
568) 
7.8 (5-12) 780 (198-
1347) 
7.4 (1.24-
53.32) 
TB 
+diabetes 
60 (36-86) 23 (16.4 -
31.1) 
214 (90-
351) 
8.8 (4-15) 687 (142-
1800) 
4.2 (1.28-
21.5) 
 
Most of the patients were overweights in both 
groups, in the diabetes group there were 55% 
normoweight and 45% overweight and in TB with co-
morbidity diabetes, there were 60% normoweight, 
30% overweight and 10% underweight. The blood 
glucose levels were not well controlled either in 
diabetes or TBs with co-morbidity diabetes group. In 
the diabetes group there were 45% well controlled 
and 55% bad controlled. Meanwhile, in the TB with 
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co-morbidity diabetes there were 35% well controlled 
and 65 % bad controlled. The immunity status in 
diabetes group was 85% good (CD4 > 500) and 15% 
bad (CD4 < 500). In the TB with co-morbidity diabetes 
75% good and 25 % bad. 
Table 2: Statistic of parameters studied in the diabetic group 
compared to those in TBs with comorbid diabetic 
 Diabetic TB +diabetic p 
Blood glucose mean 
(SD) mg/dl 
223.4 ± 117.4 214.1 ± 78.6 0.75 
HbA1c mean(SD) % 7.82 ± 1.75 8.78 ± 2.85 0.19 
CD4 mean(SD) 779.8 ± 299.9 687.2 ± 380.5 0.074 
AGEs mean(SD) 
μg/ml 
7.4 ± 10.7 4.16 ± 5.9 0.001 
BMI mean(SD) 24.6 ± 2.48 23.1 ± 3.33 0.009 
Statistical significant p < 0.05. 
 
The mean level of the AGEs was 5.78 with 
the range 1.24-53.32 in diabetes group and 1.3-19.38 
in the TB with co-morbidity diabetes group. No 
statistically significant differences were seen in blood 
glucose level (p = 0.75, HbA1C, p = 0.19 and CD4, p 
= 0.074) between the diabetes group and TB with co-
morbidity diabetes, but BMI did with p = 0.009 and so 
did AGEs with p = 0.001. 
 
Figure 1: CD4 in diabetes and TB with co-morbidity diabetes; G1: 
diabetes; G2: TB with co-morbidity diabetes 
 
In diabetes group there was no Statistical 
significant correlation found between CD4 and AGEs 
(p = 0.11), CD4 and blood glucose (p = 0.19), CD4 
and HbA1C (p = 0.09), CD4 and BMI (p = 0.48). 
Statistical significant correlation was found between 
blood glucose and HbA1C (p = 0.013, r = 0.35), blood 
glucose and AGEs (p = 0.013, r = 0.35). 
No statistical significant correlation was found 
between CD4 and AGEs (p = 0.44), CD4 and blood 
glucose (p = 0.08), CD4 and HbA1C (p = 0.45), CD4 
and BMI (p = 0.44), but between blood glucose and 
HbA1C (p = 0.003, r = 0.43), HbA1C and AGEs (p = 
0.003, r = 0.43). 
 
Figure 2: AGEs in diabetes and TB with co-morbidity diabetes; G1: 
diabetes; G2: TB with co-morbidity diabetes 
 
 
Discussion 
 
The chronic hyperglycemia will cause various 
complications; this was supported by the significant 
correlation between HbA1C and AGEs (p = 0.003) in 
the TB with co-morbidity diabetes group and 
significant correlation between blood glucose and 
AGEs (p = 0.013) in the diabetes group. This has 
been suggested by Helen et al. that AGEs play a rule 
in chronic inflammation [23].  
The body mass index of the patients in the 
diabetes group was more with normoweight (22%) 
than overweight (18%), also in the TB with co-
morbidity diabetes group (normoweight 24%, 
overweight 12%, underweight 4%). Obesity plays a 
role in metabolic syndrome that will worsen the 
chronic hyperglycemic effect. This was described by 
Ann Smith in The Epidemic of Obesity and Diabetes 
Trends and Treatments 2011 [24]. Underweight was 
found in the TB with co-morbidity diabetes group.  
The CD4 ranged between 142 and 1800 with 
the mean 733. There were more cases (25%) with 
CD4 below 500 in the TB with co-morbidity diabetes 
group than in the diabetes group (15%), assumed that 
the immunity in the diabetes group is better than the 
TB with co-morbidity diabetes group, but the data did 
not show statistical significance difference (p = 0.07). 
Advanced glycation end products that play a role in 
cell dysfunctions and diabetic complications did not 
show the correlation with CD4 (p = 0.44) in the TB 
with co-morbidity diabetes group and p = 0.114 in the 
diabetes group. In conclusion, the CD4 below 500 
were seen in 15% diabetes and 25% in TB with co-
morbidity diabetes groups, but did not show statistical 
significance difference (p = 0.07). The AGEs was not 
correlated significantly with the CD4 in both groups (p 
= 0.44, p = 0.114). The HbA1C correlated significantly 
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with AGEs (p = 0.003) in the TB with co-morbidity 
diabetes group and blood glucose with AGEs (p = 
0.013) in the diabetes group. No statistically 
significant differences were seen in blood glucose 
level (p = 0.75, HbA1C, p = 0.19 and CD4, p = 0.074) 
between the diabetes group and TB with co-morbidity 
diabetes. But BMI did with p = 0.009 and so did AGEs 
with p = 0.001. 
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